News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
473,460 Results
Type
Article (36901)
Company Profile (252)
Press Release (436307)
Section
Business (136560)
Career Advice (997)
Deals (24481)
Drug Delivery (74)
Drug Development (67661)
Employer Resources (94)
FDA (13009)
Job Trends (10378)
News (242359)
Policy (21811)
Tag
Academia (2019)
Alliances (35293)
Alzheimer's disease (1054)
Approvals (12921)
Artificial intelligence (101)
Bankruptcy (181)
Best Places to Work (8705)
Biotechnology (200)
Breast cancer (107)
Cancer (941)
Cardiovascular disease (75)
Career advice (835)
CAR-T (77)
Cell therapy (241)
Clinical research (53650)
Collaboration (308)
Compensation (121)
COVID-19 (1928)
C-suite (77)
Cystic fibrosis (81)
Data (846)
Diabetes (114)
Diagnostics (4744)
Earnings (54832)
Employer resources (88)
Events (68784)
Executive appointments (211)
FDA (13404)
Funding (269)
Gene therapy (175)
GLP-1 (464)
Government (2761)
Healthcare (13804)
Infectious disease (1987)
Inflammatory bowel disease (100)
Interviews (163)
IPO (12291)
Job creations (2001)
Job search strategy (720)
Layoffs (340)
Legal (4594)
Lung cancer (160)
Manufacturing (136)
Medical device (8365)
Medtech (8369)
Mergers & acquisitions (12302)
Metabolic disorders (331)
Neuroscience (1284)
NextGen Class of 2024 (4203)
Non-profit (2923)
Northern California (1108)
Obesity (197)
Opinion (169)
Patents (85)
People (37768)
Phase I (16884)
Phase II (23682)
Phase III (17963)
Pipeline (251)
Postmarket research (1979)
Preclinical (6931)
Radiopharmaceuticals (230)
Rare diseases (201)
Real estate (3230)
Regulatory (15502)
Research institute (2028)
Resumes & cover letters (167)
Southern California (950)
Startups (2630)
United States (10004)
Vaccines (420)
Weight loss (150)
Date
Today (217)
Last 7 days (782)
Last 30 days (2729)
Last 365 days (30466)
2024 (26384)
2023 (33559)
2022 (42328)
2021 (45263)
2020 (41220)
2019 (32426)
2018 (24606)
2017 (24733)
2016 (22786)
2015 (26393)
2014 (18979)
2013 (22442)
2012 (15682)
2011 (16112)
2010 (14669)
Location
Africa (506)
Arizona (83)
Asia (28970)
Australia (5113)
California (2445)
Canada (940)
China (193)
Colorado (90)
Connecticut (109)
Europe (67540)
Florida (336)
Georgia (81)
Illinois (202)
Indiana (141)
Maryland (412)
Massachusetts (2091)
Michigan (118)
Minnesota (194)
New Jersey (750)
New York (710)
North Carolina (593)
Northern California (1108)
Ohio (105)
Pennsylvania (626)
South America (672)
Southern California (950)
Texas (320)
Washington State (300)
473,460 Results for "jaguar gene therapy".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome
Jaguar Gene Therapy today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) Application for JAG201, a gene therapy for a genetic form of autism spectrum disorder (ASD) and Phelan-McDermid syndrome (PMS).
January 31, 2024
·
7 min read
Gene therapy
Roche Inks Potential $1B Gene Therapy Deal With Dyno, Eyes Neurological Diseases
With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’
in vivo
gene therapy delivery technology, which synthesizes virus capsids with better functionality and manufacturability.
October 24, 2024
·
2 min read
·
Tristan Manalac
Editorial
Eyes, Ears Get Their Due With Cell and Gene Therapy
With promising early results, cell and gene therapies are making headway against both rare and common ocular and auditory diseases.
September 3, 2024
·
4 min read
·
Heather McKenzie
Press Releases
Jaguar Gene Therapy to Initiate Inaugural Pediatric Clinical Trial Targeting a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome
July 9, 2024
·
6 min read
Layoffs
Astellas Gene Therapies to Close Biomanufacturing Facility, Affecting About 100 Employees
Astellas Gene Therapies is closing its San Francisco biomanufacturing facility, shifting gene therapy manufacturing to North Carolina, cutting at least 17 employees and affecting dozens more.
September 3, 2024
·
1 min read
·
Angela Gabriel
Regulatory
Sangamo’s Fabry Gene Therapy Could Hit Market 3 Years Earlier With FDA Accelerated Approval Pathway
The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy candidate, eliminating the need for an additional registrational study and potentially shortening the time-to-market by three years.
October 23, 2024
·
2 min read
·
Tristan Manalac
Deals
Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement - June 26, 2024
Jaguar Health, Inc. today announced that on June 25, 2024 the Company received formal notice from The Nasdaq Stock Market LLC that Jaguar has regained compliance with Nasdaq’s minimum bid price requirement.
June 26, 2024
·
3 min read
Cell and gene therapy
Big Pharma’s Interest Grows in Evolving Cell and Gene Therapy Sector
Large pharmaceutical companies were out in force at this week’s 2024 Cell & Gene Meeting on the Mesa, as they look to expand their presence in the industry.
October 9, 2024
·
4 min read
·
Greg Slabodkin
Business
Jaguar Health Reports First Quarter 2024 Financial Results
Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today reported consolidated first-quarter 2024 financial results and provided Company updates.
May 14, 2024
·
14 min read
Gene Therapy
Vertex, CRISPR’s Casgevy Highlights Complex Path to Gene Therapy Profitability
No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy. Experts weigh in on the path to profit for the treatment and the therapeutic class in general.
September 11, 2024
·
7 min read
·
Annalee Armstrong
1 of 47,346
Next
